New study confirms sentinel lymph node prediction accuracy, Castle Biosciences asserts

Traders Union
All News
Business & Wealth
Companies
Castle Biosciences reveals melanoma study

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Jose Antonio Gastelum

11.03.2026

New study confirms sentinel lymph node prediction accuracy, Castle Biosciences asserts — Castle Biosciences reveals melanoma study

Castle Biosciences has released new data from what it calls the largest prospective multicenter study to date for the DecisionDx-Melanoma test.

The results, presented at the SSO Annual Meeting, confirm that the integrated sentinel lymph node biopsy (i31-SLNB) test result accurately predicts sentinel lymph node (SLN) status in melanoma patients. The findings could influence clinical practice by improving risk assessment and guiding treatment decisions for individuals with melanoma. Details on the study methodology and broader clinical implications were not provided in the tweet.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

The limits of progress: Why AI development could slow down

By Oleg Tkachenko
10 hours ago

The limits of progress: Why AI development could slow down

Editors' Picks

Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?

By Dmytro Kharkov
11 hours ago

Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?

Editors' Picks

Tokens without buyers: Why NFT marketplaces are shutting down

By Mikhail Vnuchkov
Yesterday

Tokens without buyers: Why NFT marketplaces are shutting down

Editors' Picks

All Editors' Top Picks

Latest Castle News

Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026

By Oksana Koneva
Yesterday

Castle Biosciences unveils findings from three Barrett Esophagus studies at ACG 2026

Companies

Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations

By Alena Volkova
28.09.2026

Castle Biosciences study finds TissueCypher Barrett Esophagus Test led to 90 percent change in clinician recommendations

Companies

Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment

By Mikhail Vnuchkov
25.09.2026

Castle Biosciences research finds patient demand for molecular testing in atopic dermatitis treatment

Companies

All Castle News

Oleg Tkachenko
10 hours ago

The limits of progress: Why AI development could slow down

Dmytro Kharkov
11 hours ago

Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?

Mikhail Vnuchkov
Yesterday

Tokens without buyers: Why NFT marketplaces are shutting down

Alena Volkova
Yesterday

Is it bad to be rich: Why billionaires are seen as villains

Olena Litvinenko
12.10.2026

What is a national blockchain network and does the world need one?

Daria Chernytska
5 min ago

Phil Rosen: S&P 500 rises 12% despite 203 stocks negative year-to-date

Hanna Syniavska
10 min ago

Automated SaaS service connects Stripe with German accounting and delivers $120,000 in profit, Andrew Gazdecki notes

Igor Krasulya
13 min ago

Islamic legalistic tradition aids sharia finance expansion, Mike Bird notes

Mikhail Vnuchkov
15 min ago

Jim Cramer: Concern that McCormick is paying too much

Yaroslav Dmytrenko
20 min ago

$1 trillion loss from AI-linked job risks could impact U.S. banks, Luke Gromen notes

Top News

Igor Krasulya
4 hours ago

Morgan Stanley tops Wall Street estimates as equity trading revenue soars

Morgan Stanley tops Wall Street estimates as equity trading revenue soars

Ivan Andriyenko
5 hours ago

Oil prices advance amid new Iranian threats to tankers

Oil prices advance amid new Iranian threats to tankers

Ivan Andriyenko
10 hours ago

Gold slips below $4,150 as Fed rate outlook weighs on bullion

Gold slips below $4,150 as Fed rate outlook weighs on bullion

Andrey Mastykin
11 hours ago

Lagarde sees no wider inflation spillover as energy prices surge

Lagarde sees no wider inflation spillover as energy prices surge

Dmytro Kharkov
11 hours ago

Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?

Console price wall: Can Sony, Microsoft, and Nintendo still grow their installed bases at $541 average?

Top 5 companies for you

United States

Live News

Hlib Chabaniuk
Now

Hex founder Richard Heart detained in Turkey on Interpol Red Notice

Eugene Komchuk
Now

Crypto remittances from Canada to Asian countries reach nearly $2.4 billion

Aleksandra Chaikina
Now

Kraken owner Payward to acquire Lithuanian bank in EU expansion

Andrey Mastykin
Now

Wall Street futures diverge as inflation and earnings take focus

Anton Kharitonov
Now

EUR/USD faces renewed downside risks as markets await U.S. inflation report

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.